Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.1400 (-4.38%) ($11.0100 - $11.6100) on Thu. May. 14, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.1% (three month average) | RSI | 33 | Latest Price | $11.1400(-4.38%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.8% a day on average for past five trading days. | Weekly Trend | FOLD declines -2.3% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(50%) XBI(50%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -3.55% in a week (0% probabilities). VIXM(-28%) VXX(-15%) UUP(-11%) UNG(-4%) TLT(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.55% (StdDev 7.1%) | Hourly BBV | 0 () | Intraday Trend | -2.3% | | | |
|
Resistance Level | $11.91 | 5 Day Moving Average | $11.74(-5.11%) | 10 Day Moving Average | $11.72(-4.95%) | 20 Day Moving Average | $11.91(-6.47%) | To recent high | -13.1% | To recent low | 68% | Market Cap | $2.877b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |